ANAB receives $20M milestone from GSK for FDA approval of Jemperli (dostarlimab) in second-line endometrial cancer with dMMR: https://finance.yahoo.com/news/fda-approves-jemperli-dostarlimab-gxly-201200342.html Jemperli is yet another PD-1 inhibitor. There are now seven PD-(L)1 inhibitors on the US market.